Bioverse+
Online platform and community for sharing free downloadable 3D CAD models and protocols for human organs and tissues specifically for 3D bioprinting.
- CEO / Founder
- Stefan Blomsterberg
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $0 (platform of BICO Group / CELLINK)
- Latest Round
- N/A (community platform of BICO Group, not independently funded)
- Key Investors
- BICO Group (parent company, formerly CELLINK) — listed on Nasdaq Stockholm (ticker: BICO); BICO Group raised ~$450M+ since 2016 IPO
Technology & Products
Key Products
3D CAD models for human organs and tissues; Bioprinting protocols; Surgical practice models
Technological Advantage
Network effect from being the primary open-access database for bioprinting; integration with the CELLINK ecosystem provides a ready user base of bioprinter owners.
Differentiation
Value Proposition
Provides an open-source repository of standardized bioprinting models and protocols, reducing the barrier to entry for tissue engineering and surgical practice by offering free, downloadable blueprints.
How They Differentiate
Unlike closed or hard-to-access databases, Bioverse is open-access and community-driven, specifically tailored for bioprinting protocols rather than general 3D printing.
Market & Competition
Target Customers
Bioprinting researchers, clinicians, professors, students, hobbyists, and companies.
Industry Verticals
Medical; Biotechnology; Education
Competitors
NIH 3D Print Exchange, Embodi3D, and MyMiniFactory (Medical category)
Growth & Milestones
Growth Metrics
Bioverse is developed and maintained by Cellink, a leading 3D bioink and bioprinter manufacturer, and is an open-source global 3D bioprinting community with CAD models of human organs and tissue models, accessible at www.bioverse.co with email or social login for sharing and downloading blueprints and protocols.
Major Milestones
Beta launch late 2017; Official launch February 2018
Notable Customers
MIT, Harvard University, FDA, Merck, Novartis, and AstraZeneca